and/or autoimmunity. 3 - 7 Attempts to demonstrate a relation between AD and immunologic mechanisms have suggested that the amyloid substance in senile (neuritic) plaques may be derived from serum immunoglobulins (Ig), which could be explained by a leakage of serum proteins. 8 In addition, it has been suggested that elderly subjects with cognitive deficits have higher levels of IgG and IgA. 9 Interestingly, elevated titers of IgG in serum and cerebrospinal fluid have been demonstrated in multi-infarct dementia (MID) and not in AD, indi-eating a disruption of the blood-brain barrier (BBB) in patients with cerebrovascular disorders. 10 Furthermore, histopathologic studies in MID and AD with MID have shown the presence of heavy deposits of serum proteins (IgG, Clq, C3c, and fibrinogen) exclusively in capillaries of layers I-IV of the neocortical gray matter, suggesting a defect of the cortical capillary system in patients with vascular disorders and the presence of antigen-antibody (Ag-Ab) complexes in the perivascular deposits. 11 Whether these immunologic changes in MID are related to the dementing process have not been determined yet.
One possible approach to this problem is the study of serum autoantibodies against non-central nervous system tissue in patients with AD and vascular dementia (VD). Based on a common model of known autoimmune disease (e.g., diabetes mellitus, systemic lupus erythematosus, rheumatoid arthritis), patients who develop autoimmune disease frequently have autoantibodies to a variety of tissue other than the organs targeted. 12~1S This approach may allow us to predict that the presence of non-central nervous system autoantibodies would reflect an autoimmune process in the cerebral tissue of these patients. In a previous study, 16 we examined sera from 88 patients with the clinical diagnosis of probable or possible AD 17 and 55 healthy elderly controls to determine whether an excess of autoantibodies was present in AD patients. No individual autoantibody could be used to differentiate both groups, and the number of autoantibodies was not significantly different between groups. However, 14 (70%) of 20 patients with the clinical diagnosis of possible AD with cerebrovascular disease (CVD) had circulating autoantibodies.
In the present study we further analyzed the clinical significance of those findings to determine whether the immune abnormalities are part of a subgroup of AD or are associated with cerebrovascular disorders. We examined the presence of -serum autoantibodies in patients with probable AD, 17 possible AD with CVD, and VD, and in normal elderly control subjects. In addition, we investigated the sera of these patients for the presence of an antivascular Ab directed against the vascular basement membrane proteoglycan antigen and for circulating immune complexes.
Subjects and Methods
We examined data from 40 age-matched subjects: 10 with probable AD, 10 with possible AD with CVD, 10 with VD, and 10 normal elderly control subjects who were participating in a longitudinal study of dementia at the University of Pittsburgh (Pa). Each subject underwent extensive screening, including medical, neurological, psychiatric, social work/nursing, and neuropsychological examinations. Computed tomographic (CT) scans (27 patients) or magnetic resonance imaging (MRI) (13 patients) of the head, electroencephalograms, chest roentgenograms, and appropriate laboratory and blood studies were completed. Each clinical diagnosis was reached after review at a consensus conference by two board-certified neurologists. 1819 No subject was depressive or had manic or hypomanic episodes before the onset of dementia. One patient with VD was medicated with beclomethasone. Four of the 40 subjects have since died, and autopsy was performed in two patients. One patient had "definite" AD 17 and other AD with hemorrhagic infarcts in parietal and temporal lobes. Both patients died 2 years after the autoantibodies study was performed. The demographic characteristics of the subjects are shown in Table 1 .
On the basis of the clinical diagnosis, we divided the patients as follows: Probable AD: This group met the NINCDS-ADRDA clinical criteria for probable AD. 17 These were patients in whom the concomitant presence of a dementing process other than AD was excluded. The Hachinski Ischemic score was not used as an affirmative criterion for diagnosing possible A D with CVD or VD because it is known not to be specific for these disorders. 21 Autoantibody titers were determined by different laboratory procedures. Antibody to thyroglobulin and thyroid microsomal antigen (thyroid peroxidase) were determined by the indirect hemagglutination procedure using kits purchased from Miles, Inc., Elkhart, Ind. A positive titer was 100 for Ab to thyroglobulin and 400 for Ab to thyroid microsomes. Antinuclear Ab, anti-smooth muscle Ab, and gastric anti-parietal cell Ab were determined by indirect immunofluorescence on sections of mouse stomach and kidney using slides purchased from Kallestad Laboratories, Austin, Tex. A titer of 40 was considered positive.
Antiendothelial Ab was detected by immunofluorescence using fresh-frozen monkey heart sectioned at 4 fim on a cryostat and fixed in cold (4°C) acetone for 30 seconds. Sera were tested at a 1:10 and a 1:40 dilution and incubated for 30 minutes at room temperature. A goat anti-human fluorescein-labeled anti-IgG was then applied for 30 minutes. A positive control serum was included in all studies.
Rheumatoid factor was determined by fluorescence immunoassay (FIAX, M.A. Whittaker Bioproducts, Inc., Walkerville, Md.). Anticardiolipin Ab was determined by enzyme-linked immunosorbent assay (ELISA). 22 Immunocomplexes were detected by the use of a qualitative electrophoretic assay. 23 Antineuronal Ab was detected by an ELISA procedure using a saline extract of normal human hippocampus (collected within 6 hours of death) as the antigen. The protein concentration was 11 mg/dl, and the extract was coated onto 96-well, flat-bottomed microtiter plates. After blocking unbound sites with bovine serum albumin, patient and control sera were added to coated and uncoated wells, after which IgG antibody binding was detected by adding goat anti-human IgG conjugated with alkaline phosphatase. Color development was by />-nitrophenylphosphate, and a reaction was considered positive when the optical density of the color in the well containing antigen was 2.5 times that of the uncoated well.
One-way analysis of variance (ANOVA) and a contrast analysis were used to analyze Mini-Mental State scores 24 and Hachinski Rating Scale scores. 20 
Results
The patients had been matched by age. The ANOVA and post hoc comparisons with subject groups and the Mini-Mental State scores revealed a significant statistical difference between patient groups (e.g., probable AD, possible AD with CVD, VD) and normal control subjects (F 3 ,39=10.15,/?<0.001), and there was no difference among patient groups. ANOVA and post hoc comparisons within subject groups and the Hachinski Rating Scale revealed that possible AD with CVD and VD differed significantly from probable AD and normal control subjects (F 3i3 9=12.63; /;<0.001), and there was no difference between possible AD with CVD and VD (Table 1) .
Immune complexes were detected in the sera of 20-30% of each patient group. There were no significant differences between groups. Neither the patients nor control sera were found to contain antiendothelial antibody.
Autoantibodies were present in 10 of 10 (100%) possible AD with CVD patients, in 8 of 10 (80%) VD patients, in 4 of 10 (40%) probable AD patients, and in 3 of 10 (30%) normal control subjects (Table 2 ). There was a significant statistical difference when we compared the proportion of patients with autoantibodies between the groups with cerebrovascular disorders (possible AD with CVD and VD) and the groups without those characteristics (normal control subjects and probable AD) (* 2 =12.91, df=l,p<0.001). Taking advantage of the fact that patients and control subjects were matched by age, we compared groups using McNemar's test for paired categorical data. The proportion of VD patients with autoantibodies was not significantly different from that of probable AD patients (p=0.21), possible AD with CVD patients (p=0.5), and nondemented control subjects (p=0.12). However, the proportion of patients with possible AD with CVD with autoantibodies was significantly different from nondemented control subjects (p=0.01) and probable AD patients (p=0.03), and no significant difference was seen when we compared them with VD patients (p=0.5). It is important to note that the low number of patients in each group may give a low statistical power to this analysis. Table 3 shows the relation between serum autoantibodies and medication, systemic diseases, and neuroradiological findings.
No relation was observed between medication and the presence of autoantibodies. The proportion of patients with systemic disease that could affect the integrity of the cerebral blood vessels, such as hypertension, diabetes mellitus, and ischemic heart disease (atherosclerosis), was similar among groups. The diagnosis of ischemic heart disease required a history of documented myocardial infarction and/or an abnormal electrocardiogram for the presence of ischemic changes or arrhythmias. Hypertension was diagnosed by previous history and/or systolic blood pressure of > 140 mm Hg and diastolic of >90 mm Hg at the moment of the physical examination.
Discussion
The present study indicates that serum autoantibodies were present in 100% of the patients with possible AD with CVD, 80% of those with VD, and 40% of those with probable AD and in 30% of normal control subjects. No individual autoantibody could differentiate AD from cerebrovascular disorders or demented patients from control subjects. However, antinuclear Ab was present in 60% of VD patients and antineuronal Ab in 50%. Assays to detect the presence of antiendothelial Ab and circulating immune complexes did not differentiate the patient groups. No relation was observed between medication and systemic disease and the presence of autoantibodies. However, one patient with VD was medicated with beclomethasone, which could have a suppressive effect on some autoantibodies. 25 Antinuclear and antineuronal antibodies were more frequent in VD patients than in the other groups examined. It is possible that the antineuronal Ab occurs after tissue damage associated with vascular occlusion. Antigens from damaged tissue may enter the systemic circulation and stimulate an Ab response. Whether such Ab interferes with normal cell function and contributes to the dementia observed in these patients could not be determined by these studies. Antineuronal Ab has been associated with neuropsychiatric manifestation in systemic lupus erythematosus patients. 26 " 29 The mechanisms involved in the antineuronal Ab clinical manifestations are unknown. However, its presence in the serum and cerebrospinal fluid of systemic lupus erythematosus patients indicated a BBB dysfunction. Although the clinical significance of antineuronal Ab in non-systemic lupus erythematosus patients is less well demonstrated, the presence of antineuronal Ab in the serum of VD patients may also indicate a BBB dysfunction and an underlying cerebral immunological process. The role of antinuclear Ab in VD is less clear than that of antineuronal Ab. It has been reported that antinuclear Ab increases with age, and some authors linked its presence to the aging process. 30 However, in systemic lupus erythematosus patients the presence of antinuclear Ab has been associated with cerebral infarction, especially when it is accompanied with antiphospholipid antibodies. 31 Atherosclerotic angiopathy 32 and cerebral amyloid angiopathy 33 with secondary vascular changes (i.e., infarcts and hemorrhages) may be partially or wholly responsible for deficits in the permeability of the BBB 34 - 35 and the transudation of serum proteins to the central nervous system in VD or in AD with CVD. 10 Similarly, cerebral angiopathies may also explain the presence of central nervous system autoantibodies in the serum of demented patients. In addition, it has been demonstrated that the degree of permeability was as pronounced in MID as in CVD patients, 34 indicating that cerebral softenings per se were not the only cause of BBB dysfunction. In our study, subjects showed no symptoms or signs of cerebral ischemic events within 6 months before the serum examination. Thus, it seems unlikely that infarcts could have caused increased BBB permeability. Furthermore, autoantibodies were most common in patients with CT scans or MRI of the head that reflected chronic vascular disorders, either evident ischemic infarcts or periventricular white matter lesions. 36 - 37 Interestingly, three of the four patients with probable AD with autoantibodies showed small cerebral infarcts in neuroradiological studies. None of these patients had transient ischemic attacks or episodes of loss of consciousness from cardiovascular problems. These findings indicate the importance of small-vessel disease in dementia processes and suggest an association with the presence of circulating autoantibodies.
One possibility examined in this study is that circulating autoantibodies may reflect a predisposition to develop autoantibodies to vascular endothelial cells. Fillit et al 5 previously used immunofluorescence to detect antiendothelial Ab in patients with dementia. The authors found that six of 16 AD patients examined had an antivascular Ab and suggested that an autoimmune injury to the BBB by antivascular Ab may play a role in the pathogenesis of dementia by permitting the passage of injurious substances into the brain. However, assays to detect the presence of antiendothelial Ab were negative in all groups examined in this study. Another possibility examined involved the presence of immune complexes that deposit in the vessel walls, activate the complement system, and lead to vessel damage, as suggested by Alafuzoff et al. 11 However, we failed to reveal a difference in the frequency of immune complexes between various groups studied.
Although demented patients with cerebrovascular disorders met our criteria for either CVD or VD, questions may arise about low scores and the lack of statistical difference between both groups on the Hachinski Rating Scale. This brings to light a current problem in the classification of cerebrovascular disorders in an ambulatory population with dementia who have not suffered major ischemic or hemorrhagic lesions on the brain. Some such patients have clinical evidence of stroke for which there are no corresponding focal neuroradiological lesions at the time of the examination, whereas others have focal lesions on the CT or MRI scan of the brain for which no focal neurological signs or history of stroke can be established. These observations indicate that the relation between dementia and vascular lesions is not yet completely understood. Similar cerebral vascular lesions and clinical presentation can be seen in nondemented individuals, suggesting that factors other than infarcts may be involved, especially in the etiology of VD. These data seem to favor a multifactorial etiology of VD 38 in which not only infarcts but also a small-vessel disease and an autoimmune process seem to play a role. Whether the concomitant presence of AD contributes to the immunologic disorder observed in CVD patients is unknown. However, in the present study, patients with AD and CVD had more autoantibodies than other groups, and, as noted above, three of the four patients with probable AD with autoantibodies had small cerebral infarcts, indicating the presence of a cerebrovascular disorder but without clinical manifestation of CVD. Despite the relatively small number of individuals examined in this study, the presence of autoantibodies may indicate a link between an autoimmune process and CVD in dementia.
